Cancer Research Technology and the University of Barcelona have initiated a collaboration to develop AT514 (serratamolide) and analogues for the treatment of cancer
Cancer Research Technology (CRT, the specialist oncology development and commercialisation company) and the University of Barcelona have initiated a collaboration to develop AT514 (serratamolide) and analogues for the treatment of cancer.
AT514 is a microbial depsipeptide, identified as an anti-cancer agent by scientists at the University of Barcelona.
The University of Barcelona will conduct development studies in collaboration with CRT and have assigned the rights to the use of AT514 in the treatment of cancer to CRT.
Commercialisation of AT514 will be led by CRT and both parties will share future revenues.
This is the first collaboration between CRT and the University of Barcelona.
It is hoped that this partnership will result in the generation of an important new cancer therapy and lead to further joint oncology drug development and commercialisation projects.
